Detalhe da pesquisa
1.
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
N Engl J Med
; 390(4): 301-313, 2024 Jan 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-38084760
2.
Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study.
Lancet
; 398(10306): 1157-1169, 2021 09 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-34508654
3.
Subcutaneous daratumumab plus standard treatment regimens in patients with multiple myeloma across lines of therapy (PLEIADES): an open-label Phase II study.
Br J Haematol
; 192(5): 869-878, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33216361
4.
Palliative care in patients with haematological neoplasms: An integrative systematic review.
Palliat Med
; 32(1): 79-105, 2018 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29130387
5.
Results of an Early Access Treatment Protocol of Daratumumab Monotherapy in Spanish Patients With Relapsed or Refractory Multiple Myeloma.
Hemasphere
; 4(3): e380, 2020 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-32647799
6.
Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS.
Blood Cancer J
; 13(1): 33, 2023 03 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-36882409
7.
Is Early Palliative Care Feasible in Patients With Multiple Myeloma?
J Pain Symptom Manage
; 54(5): 692-700, 2017 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-28807703